Literature DB >> 15807471

Neuroendocrine tumors of the appendix.

Norman J Carr1, Leslie H Sobin.   

Abstract

The vast majority of neuroendocrine neoplasms of the appendix are carcinoid tumors. Most are of enterochromaffin (EC) cell type, although rare examples are of L cell type. EC cell carcinoids of the appendix differ from those encountered elsewhere in the gastrointestinal system. For example, they are remarkably common given the small size of the appendix, are usually benign, occur in younger patients, and typically contain sustentacular cells that express S-100. Origin from subepithelial neuroendocrine cells could explain these characteristics. It has also been suggested that most appendiceal carcinoids are hyperplastic rather than neoplastic, although this hypothesis requires further study. Nevertheless, truly neoplastic EC cell carcinoids of the appendix undoubtedly occur, and those greater than 2 cm in diameter have a significant risk of producing distant metastases. Carcinoid syndrome is a very rare presentation. Tubular carcinoids are unusual benign neoplasms; it has been proposed that they represent L cell carcinoids with a predominant tubular pattern of growth. Goblet cell carcinoids tend not to produce a grossly visible tumor mass but diffusely infiltrate the wall. They typically exhibit tight clusters of goblet cells, usually with scattered neuroendocrine cells and sometimes with Paneth cells, sometimes surrounding a small lumen. They may behave as a low-grade malignancy. The distinction between goblet cell carcinoid and other types of tumor is of great importance because of the implications for treatment and prognosis. Frank adenocarcinoma can arise from goblet cell carcinoids, and tumors with both components are classified as mixed goblet cell carcinoid-adenocarcinoma. The carcinoma component of the latter determines their prognosis, which would be worse than for a goblet cell carcinoid alone.

Entities:  

Mesh:

Year:  2004        PMID: 15807471     DOI: 10.1053/j.semdp.2004.11.004

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  6 in total

1.  Management of gastrointestinal carcinoid tumours - 10 years experience at a district general hospital.

Authors:  Shridhar S Dronamraju; Vickram B Joypaul
Journal:  J Gastrointest Oncol       Date:  2012-06

2.  Epidemiology of neuroendocrine tumors of the appendix in the USA: a population-based national study (2014-2019).

Authors:  Motasem Alkhayyat; Mohannad Abou Saleh; Wendy Coronado; Mohammad Abureesh; Mohammad Zmaili; Thabet Qapaja; Ashraf Almomani; George Khoudari; Emad Mansoor; Gregory Cooper
Journal:  Ann Gastroenterol       Date:  2021-06-14

Review 3.  Carcinoid tumor of the appendix: a consecutive series from 1237 appendectomies.

Authors:  Vincent Tchana-Sato; Olivier Detry; Marc Polus; Albert Thiry; Bernard Detroz; Sylvie Maweja; Etienne Hamoir; Thierry Defechereux; Carla Coimbra; Arnaud De Roover; Michel Meurisse; Pierre Honoré
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

Review 4.  Appendiceal Nodules in the Setting of Endometriosis Can Be Carcinoid Tumors.

Authors:  Igor Leonardo Padovesi Mota; Sidney Klajner; Manoel Orlando da Costa Gonçalves; Leigh J Passman; Sergio Podgaec
Journal:  JSLS       Date:  2015 Jul-Sep       Impact factor: 2.172

5.  Histopathology of gastrointestinal neuroendocrine neoplasms.

Authors:  Kenichi Hirabayashi; Giuseppe Zamboni; Takayuki Nishi; Akira Tanaka; Hiroshi Kajiwara; Naoya Nakamura
Journal:  Front Oncol       Date:  2013-01-22       Impact factor: 6.244

6.  Neuroendocrine appendiceal tumor and endometriosis of the appendix: a case report.

Authors:  Rogério Serafim Parra; Marley Ribeiro Feitosa; Giovana Bachega Badiale Biagi; Daniel Ferracioli Brandão; Margarida Maria Fernandes da Silva Moraes; Liliane Silvestre; José Vitor Cabral Zanardi; Nelson Hitamo Sato Junior; Omar Féres; José Joaquim Ribeiro da Rocha
Journal:  J Med Case Rep       Date:  2020-09-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.